Table 2.
Development and design of the EuroFlow BCP-ALL MRD panel
| Phase | Violet laser | Blue laser | Red laser | |||||
|---|---|---|---|---|---|---|---|---|
| Initial* | PB | PO | FITC | PE | PerCP Cy5.5 | PECy7 | APC | APC H7 |
| CD20 | CD45 | CD58 | CD66c | CD34 | CD19 | CD10 | CD38 | |
| CD9 | CD45 | TdT | CD13 | CD34 | CD19 | CD22 | CD24 | |
| CD21 | CD45 | CD15/CD65 | NG2 | CD34 | CD19 | CD123 | CD81 | |
| 1 | PB | PO | FITC | PE | PerCP Cy5.5 | PECy7 | APC | APC H7 |
| CD20 | CD45 | CD58 | CD66c | CD34 | CD19 | CD10 | CD38 | |
| CD20 | CD45 | TdT | SmIgK/L | CD34 | CD19 | CD10 | CD24 | |
| CD20 | CD45 | CD9 | CD123 | CD34 | CD19 | CD10 | CD81 | |
| 2 | PB | PO | FITC | PE | PerCP Cy5.5 | PE Cy7 | APC | APC H7 |
| CD20 | CD45 | CD9 | CD22 | CD34 | CD19 | CD10 | CD38 | |
| CD20 | CD45 | CD123 | CD66c | CD34 | CD19 | CD10 | CD24 | |
| 3 | PB | PO | FITC | PE | PerCP Cy5.5 | PE Cy7 | APC | APC C750 |
| CD20 | CD45 | CD9 (ML13) | CD66c/CD123 | CD34 | CD19 | CD10 | CD38 | |
| CD20 | CD45 | CD58 | CD22 | CD34 | CD19 | CD10 | CD81 | |
| 4 | PB | PO | FITC | PE | PerCP Cy5.5 | PE Cy7 | APC | APC C750 |
| CD20 | CD45 | CD81 | CD66c/CD123 | CD34 | CD19 | CD10 | CD38 | |
| CD20 | CD45 | CD81 | CD73/CD304 | CD34 | CD19 | CD10 | CD38 | |
Markers that were changed as compared with the previous panel are marked in boldface.
*
Only tubes 1, 3, and 4 of the EuroFlow BCP-ALL diagnosis panel were evaluated, because most markers in tube 2 (Cyµ, SmIgK, SmIgL, SmIgM) were not expected to contribute to separation of normal and malignant BCP cells.